CAS 146939-27-7|Ziprasidone
| Common Name | Ziprasidone | ||
|---|---|---|---|
| CAS Number | 146939-27-7 | Molecular Weight | 412.94 |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 554.8±50.0 °C at 760 mmHg |
| Molecular Formula | C21H21ClN4OS | Melting Point | 213-215°C |
| MSDS | / | Flash Point | 289.3±30.1 °C |
| Symbol | GHS02, GHS07, GHS08 | Signal Word | Danger |
Names
| Name | ziprasidone |
|---|---|
| Synonym | More Synonyms |
Ziprasidone BiologicalActivity
| Description | Ziprasidone(CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.IC50 value:Target: 5-HT receptor; Dopamine receptorZiprasidone possesses an in vitro 5-HT2A/dopamine D2 receptor affinity ratio higher than any clinically available antipsychotic agent. In vivo, ziprasidone antagonizes 5-HT2A receptor-induced head twitch with 6-fold higher potency than for blockade of d-amphetamine-induced hyperactivity, a measure of central dopamine D2 receptor antagonism. Ziprasidone also has high affinity for the 5-HT1A, 5-HT1D and 5-HT2C receptor subtypes, which may further enhance its therapeutic potential [1]. Ziprasidone sulfoxide and sulfone were the major metabolites in human serum. The affinities of the sulfoxide and sulfone metabolites for 5-HT2 and D2 receptors are low with respect to ziprasidone, and are thus unlikely to contribute to its antipsychotic effects [2]. Ziprasidone was associated with significant differential adverse effects relative to placebo in BPM, BPD, and schizophrenia with no significant difference in weight gain in all 3 groups. Self-reported somnolence was increased across the 3 conditions. Subjects with BPM were more vulnerable to EPS than those with BPD or schizophrenia [3].Clinical indications: Bipolar I disorder; Bipolar disorder; Mania; SchizophreniaFDA Approved Date: February 2001 |
|---|---|
| Related Catalog | Signaling Pathways >>GPCR/G Protein >>5-HT ReceptorSignaling Pathways >>Neuronal Signaling >>5-HT ReceptorSignaling Pathways >>GPCR/G Protein >>Dopamine ReceptorSignaling Pathways >>Neuronal Signaling >>Dopamine ReceptorResearch Areas >>Neurological Disease |
| References | [1]. Seeger, T.F., et al., Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther, 1995. 275(1): p. 101-13. [2]. Prakash, C., et al., Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos, 1997. 25(7): p. 863-72. [3]. Gao, K., et al., Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. J Clin Psychopharmacol, 2013. 33(3): p. 425-31. |
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 554.8±50.0 °C at 760 mmHg |
| Melting Point | 213-215°C |
| Molecular Formula | C21H21ClN4OS |
| Molecular Weight | 412.94 |
| Flash Point | 289.3±30.1 °C |
| PSA | 76.71000 |
| LogP | 4.00 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.681 |
| InChIKey | MVWVFYHBGMAFLY-UHFFFAOYSA-N |
| SMILES | O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1 |
| Storage condition | Refrigerator |
Safety Information
| Symbol | GHS02, GHS07, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H225-H315-H360FD |
| Supplemental HS | May form explosive peroxides. |
| Precautionary Statements | P201-P210-P308 + P313-P403 + P235 |
| Hazard Codes | C,N |
| Risk Phrases | R22:Harmful if swallowed. R34:Causes burns. R50/53:Very Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment . R20/21/22:Harmful by inhalation, in contact with skin and if swallowed . |
| Safety Phrases | S26-S36/37/39-S45-S60-S61 |
| RIDADR | UN 3259 8/PG 3 |
| WGK Germany | 2 |
| RTECS | JR6475000 |
| Packaging Group | II |
| Hazard Class | 8 |
| HS Code | 29211980 |
Customs
| HS Code | 29211980 |
|---|
Articles28
More Articles| Gingival pain: an unusual side effect of ziprasidone. BMJ Case Rep. 2013 , doi:10.1136/bcr-2012-007577, (2013) The patient is a 52-year-old man with schizophrenia who developed severe, unremitting gingival pain after his ziprasidone dosage was increased from 80 to 120 mg. His physical examination and laborator... | |
| A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J. Clin. Psychopharmacol. 33(1) , 3-10, (2013) The potential for iloperidone, a D2/5-HT2A antipsychotic, to affect the heart rate-corrected QT interval (QTc) was assessed in the absence and presence of metabolic inhibitors in a randomized, open-la... | |
| Association between second-generation antipsychotics and changes in body mass index in adolescents. J. Adolesc. Health 52(3) , 336-43, (2013) To assess the association of second-generation antipsychotics (SGAs) with changes in body mass index (BMI) among adolescents compared with a matched untreated comparison group.A retrospective cohort s... |
Synonyms
| 5-{2-4-(1,2-benzothiazol-3-yl)piperazin-1-ylethyl}-6-chloro-1,3-dihydro-2H-indol-2-one |
| 5-{2-[4-(1,2-Benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one |
| ziprasidonum |
| Ziprasidone |
| UNII-6UKA5VEJ6X |
| 5-{2-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one |
| ziprasidona |
| EINECS 203-794-9 |
| 5-{2-[4-(1,2-Benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chlor-1,3-dihydro-2H-indol-2-on |
| Zipwell |
| MFCD00866661 |
| 2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro- |
| 2H-indol-2-one, 5-2-4-(1,2-benzisothiazol-3-yl)-1-piperazinylethyl-6-chloro-1,3-dihydro- |
| 5-{2-[4-(1,2-Benzothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one |
| ziprazidone |
| Ziprasidone [INN:BAN] |
| Geodon |
| Zeldox |
| 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one |
